Ser438
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser438  -  K8 (mouse)

Site Information
sSYGGLTsPGFSYGM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448540

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 2 ) , mass spectrometry ( 1 , 3 , 4 , 5 , 6 ) , phospho-antibody ( 2 , 7 , 8 , 9 ) , western blotting ( 2 , 9 )
Relevant cell line - cell type - tissue:
hepatocyte-liver ( 7 , 9 ) , liver ( 1 , 2 , 3 , 4 , 5 , 8 )

Upstream Regulation
Putative in vivo kinases:
P38A (mouse) ( 7 )
Treatments:
DDC ( 9 ) , griseofulvin ( 2 , 8 ) , SB202190 ( 7 )

Downstream Regulation
Effects of modification on K8:
intracellular localization ( 9 ) , molecular association, regulation ( 7 )
Effects of modification on biological processes:
cytoskeletal reorganization ( 9 )

References 

1

Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83
23140645   Curated Info

2

Fortier AM, Riopel K, D├ęsaulniers M, Cadrin M (2010) Novel insights into changes in biochemical properties of keratins 8 and 18 in griseofulvin-induced toxic liver injury. Exp Mol Pathol 89, 117-25
20643122   Curated Info

3

Guo A (2009) CST Curation Set: 7790; Year: 2009; Biosample/Treatment: tissue, liver/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

4

Zhou J (2009) CST Curation Set: 7435; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

5

Zhou J (2009) CST Curation Set: 7434; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

6

Rikova K (2008) CST Curation Set: 4508; Year: 2008; Biosample/Treatment: cell line, MD Ander 1154/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

7

Nan L, et al. (2006) Mallory body (cytokeratin aggresomes) formation is prevented in vitro by p38 inhibitor. Exp Mol Pathol 80, 228-40
16563375   Curated Info

8

Fausther M, Villeneuve L, Cadrin M (2004) Heat shock protein 70 expression, keratin phosphorylation and Mallory body formation in hepatocytes from griseofulvin-intoxicated mice. Comp Hepatol 3, 5
15307891   Curated Info

9

Stumptner C, et al. (2000) Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a mallory body mouse model. Am J Pathol 156, 77-90
10623656   Curated Info